A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.

about

A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: an observational prospective study.Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.Cardiac Delayed Rectifier Potassium Channels in Health and Disease.

P2860

Q33712294-6F1F17BC-D86E-4603-B2F1-E5C27927DBFF Q38103541-2966CA0D-C80E-4E70-9638-C84A19C4D7DA Q38854252-E931676C-EC2F-4654-AC2C-F42C647078C5

P2860

A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.

Item

http://www.wikidata.org/entity/Q38080598

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A new antiarrhythmic drug in t ...... ial fibrillation: vernakalant.

@en

type

Item

label

A new antiarrhythmic drug in t ...... ial fibrillation: vernakalant.

@en

prefLabel

A new antiarrhythmic drug in t ...... ial fibrillation: vernakalant.

@en

P1476

A new antiarrhythmic drug in t ...... rial fibrillation: vernakalant

@en

P2093

Antonio Curnis

http://www.w3.org/2001/XMLSchema#string

Antonio D'Aloia

http://www.w3.org/2001/XMLSchema#string

Enrico Vizzardi

http://www.w3.org/2001/XMLSchema#string

Francesca Salghetti

http://www.w3.org/2001/XMLSchema#string

Ivano Bonadei

http://www.w3.org/2001/XMLSchema#string

P2860

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Atrial fibrillation after cardiac surgery.

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.

Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation.

Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.

Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.

A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

P304

e55-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1755-5922.12026

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sandro Gelsomino

Roberto Lorusso

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235520195

http://www.w3.org/2001/XMLSchema#string

P698

23398692

http://www.w3.org/2001/XMLSchema#string

A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.

about

P2860

P2860

A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698